Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) EPS (Basic) (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed EPS (Basic) for 11 consecutive years, with -$75.85 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 99.73% to -$75.85 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$90.87 through Dec 2025, up 99.69% year-over-year, with the annual reading at -$87.27 for FY2025, 99.72% up from the prior year.
  • EPS (Basic) hit -$75.85 in Q4 2025 for Aptevo Therapeutics, down from -$2.23 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $38.99 in Q4 2023 to a low of -$27750.5 in Q4 2024.
  • Historically, EPS (Basic) has averaged -$1653.6 across 5 years, with a median of -$1.74 in 2021.
  • Biggest five-year swings in EPS (Basic): skyrocketed 4204.07% in 2023 and later crashed 71275.69% in 2024.
  • Year by year, EPS (Basic) stood at -$1.27 in 2021, then rose by 25.2% to -$0.95 in 2022, then surged by 4204.07% to $38.99 in 2023, then plummeted by 71275.69% to -$27750.5 in 2024, then skyrocketed by 99.73% to -$75.85 in 2025.
  • Business Quant data shows EPS (Basic) for APVO at -$75.85 in Q4 2025, -$2.23 in Q3 2025, and -$8.4 in Q2 2025.